ClinicalTrials.gg
CompletedNCT01191944Updated Oct 31, 2014Results posted

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

A Phase 3 interventional study of pramipexole immediate release tablet and pramipexole extended release tablet in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 20 sites in China. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-10-31.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
475
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
7th of 26
475 · median 224
Started
2010
the only one that year
Phase 3
11 of 26
none open now
Registered
16th of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 7th largest by enrollment, is the only one that started in 2010, is one of 11 in phase 3, and was the 16th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

The objective of this trial is to evaluate non-inferiority of pramipexole Extended release to Immediate release at 18 weeks on the primary efficacy endpoint (Unified Parkinson's Disease Rating Scale II+III) in Chinese PD patients who can be concomitantly treated with Levodopa .

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female Chinese patient with idiopathic Parkinson's disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity.
  2. Parkinson's disease diagnosed for at least 2 years.
  3. Patients 30 years of age or older at the time of diagnosis.
  4. Modified Hoehn and Yahr stage of 2 to 4 at on-time.
  5. If a patient is treated with standard or controlled release Levodopa combined with a Dopa-Decarboxylase-inhibitor or with Levodopa combined with a Dopa-Decarboxylase-inhibitor/entacapone, the dosage should be optimised according to investigator's judgement, and stable for at least 4 weeks prior to baseline visit.
  6. If a patient treated with Levodopa combined with a Dopa-Decarboxylase-inhibitor has motor fluctuations, he should not have more than 6 hours of off-time every day during waking hours (documented on a patient diary completed for 2 consecutive days before baseline visit).
  7. Patient willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures (in particular, after training, the patient should be able to recognise the off-time and on-time periods during waking hours and to record them accurately in the patient diary).
  8. Signed obtained before any study procedures are carried out (in accordance with International Conference on Harmonisation-Good Clinical Practice guidelines and local legislation).

Exclusion criteria

Exclusion criteria:

Medical exclusions:

  1. Atypical parkinsonian syndromes due to drugs (e.g., metoclopramide, flunarizine), metabolic disorders (e.g., Wilson's disease), encephalitis or degenerative diseases (e.g., progressive supranuclear palsy).
  2. Dementia, as defined by a score \< 24 at screening visit [R96-2656].
  3. Any psychiatric disorder according to (4th edition)criteria that could prevent compliance or completion of the study and/or put the patient at risk if he/she takes part in the study.
  4. History of psychosis, except history of drug induced hallucinations (provided the investigator considers that participation to the trial would not represent a significant risk for the patient).
  5. History of deep brain stimulation
  6. abnormalities at screening visit, according to investigator's judgement.
  7. Clinically significant hypotension (i.e. supine systolic blood pressure \< 90 mmHg) and/or symptomatic orthostatic hypotension (i.e. clinical symptoms of orthostatic hypotension associated with a decline >=20 mmHg in systolic blood pressure and a decline >= 10 mmHg in diastolic blood pressure, at one minute after standing compared with the previous supine systolic and diastolic blood pressure obtained after 5 minutes of quiet rest) at screening or baseline visit.
  8. Malignant melanoma or history of previously treated malignant melanoma.
  9. Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the study.
  10. Pregnancy (to be excluded by urine pregnancy test at screening visit) or breast-feeding.
  11. Sexually active female of (less than 6 months and not surgically sterilised) not using a medically approved method of (i.e. oral contraceptives, intrauterine device, or double-barrier) for at least one month prior to the screening visit and throughout the study period (up to the follow-up visit).
  12. Serum levels of , Alanine Aminotransferase , alkaline phosphatases or total > 2 (on screening lab test).
  13. Patients with a \< 50 mL/min/1.73m2 (estimated by the local lab / the investigator using the Modification of Diet in Renal Disease (), and calculated on screening lab test)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
475 participants (actual)

Study arms

  • Experimental
    pramipexole Extended release

    subjects will receive 0.375mg once a day to 4.5mg once a day depending on investigator's judgement

    Drug: pramipexole extended release tablet

  • Active comparator
    pramipexole Immediate release

    subjects will receive 0.125mg three times a day to 1.0mg three times a day depending on investigator's judgement

    Drug: pramipexole immediate release tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Unified Parkinsons Disease Rating Scale (UPDRS) Parts II+III Score at Week 18

    UPDRS total score ranges from 0 (best) to 160 (worst) and was calculated as the sum of Part II (activities of daily living, ranges from 0 to 52) and Part III (motor examination, ranges from 0 to 108). Reduction over time represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

Secondary outcomes

  1. Change From Baseline in Percentage Off-time During Waking Hours at Week 18

    Percentage off-time during waking hours based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease). Reduction over time represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  2. Change From Baseline in Duration of Off-time During Waking Hours at Week 18

    Duration of off-time during waking hours based on patient diary data. Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease). Reduction over time represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  3. Responder in Percentage Off-time During Waking Hours at Week 18

    Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease). Reduction over time represents an improvement. Responders were defined as patients with at least a 20 percent improvement relative to baseline.

    Time frame: Baseline and week 18

  4. Change From Baseline in Percentage On-time Without Dyskinesia at Week 18

    Percentage on-time without Dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Increase in the percentage represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  5. Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18

    Percentage on-time with non-troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as non-troublesome if it did not interfere with function or did not cause meaningful discomfort. Increase in the percentage represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  6. Change From Baseline in Percentage On-time Without or With Non-troublesome Dyskinesia at Week 18

    Percentage on-time without or with non-troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as non-troublesome if it did not interfere with function or did not cause meaningful discomfort. Increase in the percentage represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  7. Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18

    Percentage on-time with troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as troublesome if it interfered with function or caused meaningful discomfort. Decrease in the percentage represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  8. Change From Baseline in Duration of On-time Without Dyskinesia at Week 18

    Duration of on-time without Dyskinesia based on patient diary data. On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Increase in the duration represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  9. Change From Baseline in Duration of On-time With Non-troublesome Dyskinesia at Week 18

    Duration on-time with non-troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as non-troublesome if it did not interfere with function or did not cause meaningful discomfort. Increase in the duration represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  10. Change From Baseline in Duration of On-time Without or With Non-troublesome Dyskinesia at Week 18

    Duration of on-time without Dyskinesia or with non-troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as non-troublesome if it did not interfere with function or did not cause meaningful discomfort. Increase in the duration represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  11. Change From Baseline in Duration of On-time With Troublesome Dyskinesia at Week 18

    Duration of on-time with troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as troublesome if it interfered with function or caused meaningful discomfort. Decrease in the duration represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  12. Clinical Global Impression of Improvement (CGI-I) Responder at Week 18

    CGI-I was used to assess the overall status of Parkinsons disease (PD) after interviewing the patient about the various aspects of the PD and after evaluating adverse events and concomitant treatments. Ranging from 1 point=very much improved to 7 points=very much worse. Responders were defined as patients having score 1 or 2 (at least much improved) when comparing the past week to the assessment at baseline.

    Time frame: 18 weeks

  13. Patient Global Impressions of Improvement (PGI-I) Responder at Week 18

    The PGI-I scale is a patient-rated instrument which was used to measure the improvement of a patients PD symptoms throughout the study. Ranging from 1 point=very much better to 7 points=very much worse. Responders were defined as patients having score 1 or 2 (at least much better) when comparing the past week to the assessment at baseline.

    Time frame: 18 weeks

  14. Responder in UPDRS Parts II+III Score at Week 18

    Responders were defined as patients with at least a 20 percent improvement of UPDRS II+III score relative to baseline. UPDRS II+III ranges 0-160 scores from best to worst and was calculated as the sum of Part II (activities of daily living, ranges from 0 to 52) and Part III (motor examination, ranges from 0 to 108).

    Time frame: Baseline and week 18

  15. Change From Baseline in UPDRS II Score Separately at Week 18

    UPDRS Part II (activities of daily living) ranges from 0 to 52. Reduction over time represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  16. Change From Baseline in UPDRS III Score Separately at Week 18

    UPDRS Part III (motor examination) ranges from 0 to 108. Reduction over time represents an improvement. Means are adjusted for treatment, centre and baseline.

    Time frame: Baseline and week 18

  17. Levodopa (L-Dopa) Introduction During the Study

    Number of patients without concomitant L-Dopa treatment at baseline which required L-Dopa supplementation during the study.

    Time frame: 18 weeks

  18. Levodopa (L-Dopa) Dose Change During the Study

    Although the number of patients who began the study with concomitant L-dopa supplementation and required a change in dosage was not analysed for this study, the change from baseline in L-dopa dose is presented.

    Time frame: 18 weeks

Other outcomes

  1. Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at 18 Weeks

    ESS is a patient-report scale with 8 items rating how likely one is to fall asleep during passive and inconsequential situations such as watching television, more active situations such as sitting and talking to someone, or consequential situations such as sitting in a car, while stopped for a few minutes in traffic. The likelihood of dozing off is rated from 0 points (no chance) to 3 points (high chance). The overall rating scale is scored from 0 (no daytime sleep) to 24 (worst daytime sleep).

    Time frame: Baseline and week 18

07

Results

Posted Jan 24, 2013

Participant flow

Participant flow — Overall Study
MilestonePramipexole ERPramipexole IR
Started234239
Completed217220
Not completed1719
Withdrew: Adverse event1112
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject42
Withdrew: Other13

Outcome measures

PrimaryChange From Baseline in Unified Parkinsons Disease Rating Scale (UPDRS) Parts II+III Score at Week 18

UPDRS total score ranges from 0 (best) to 160 (worst) and was calculated as the sum of Part II (activities of daily living, ranges from 0 to 52) and Part III (motor examination, ranges from 0 to 108). Reduction over time represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Unified Parkinsons Disease Rating Scale (UPDRS) Parts II+III Score at Week 18
Units on a scalePramipexole ERPramipexole IR
Change From Baseline in Unified Parkinsons Disease Rating Scale (UPDRS) Parts II+III Score at Week 18-13.807 ± 0.6547-13.047 ± 0.6434
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = <0.0001 (one-sided test relative to NI margin of -4) · Mean difference (final values): 0.760 · 95% CI -1.047 to 2.566Pramipexole IR minus Pramipexole ER, Pramipexole ER non inferior to Pramipexole IR if lower limit of confidence interval (CI) for the mean difference is higher than NI margin.
SecondaryChange From Baseline in Percentage Off-time During Waking Hours at Week 18

Percentage off-time during waking hours based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease). Reduction over time represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · Percentage off-time
Change From Baseline in Percentage Off-time During Waking Hours at Week 18
Percentage off-timePramipexole ERPramipexole IR
Change From Baseline in Percentage Off-time During Waking Hours at Week 18-6.962 ± 1.5072-7.443 ± 1.5362
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.8261 · Mean difference (final values): -0.480 · 95% CI -4.787 to 3.826
SecondaryChange From Baseline in Duration of Off-time During Waking Hours at Week 18

Duration of off-time during waking hours based on patient diary data. Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease). Reduction over time represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · hours
Change From Baseline in Duration of Off-time During Waking Hours at Week 18
hoursPramipexole ERPramipexole IR
Change From Baseline in Duration of Off-time During Waking Hours at Week 18-1.044 ± 0.2256-1.098 ± 0.2300
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.8698 · Mean difference (final values): -0.054 · 95% CI -0.699 to 0.592
SecondaryResponder in Percentage Off-time During Waking Hours at Week 18

Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease). Reduction over time represents an improvement. Responders were defined as patients with at least a 20 percent improvement relative to baseline.

Time frame:
Baseline and week 18
Reported as:
Number · Participants
Responder in Percentage Off-time During Waking Hours at Week 18
ParticipantsPramipexole ERPramipexole IR
Responder5859
Non-Responder5247
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · Cochran-Mantel-Haenszel · p = 0.7902
SecondaryChange From Baseline in Percentage On-time Without Dyskinesia at Week 18

Percentage on-time without Dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Increase in the percentage represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · Percentage of on-time
Change From Baseline in Percentage On-time Without Dyskinesia at Week 18
Percentage of on-timePramipexole ERPramipexole IR
Change From Baseline in Percentage On-time Without Dyskinesia at Week 187.028 ± 1.92744.265 ± 1.9643
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.3223 · Median difference (final values): -2.763 · 95% CI -8.255 to 2.729
SecondaryChange From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18

Percentage on-time with non-troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as non-troublesome if it did not interfere with function or did not cause meaningful discomfort. Increase in the percentage represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · Percentage of on-time
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18
Percentage of on-timePramipexole ERPramipexole IR
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18-0.235 ± 1.08073.275 ± 1.1013
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.0254 · Mean difference (final values): 3.510 · 95% CI 0.437 to 6.583
SecondaryChange From Baseline in Percentage On-time Without or With Non-troublesome Dyskinesia at Week 18

Percentage on-time without or with non-troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as non-troublesome if it did not interfere with function or did not cause meaningful discomfort. Increase in the percentage represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · Percentage of on-time
Change From Baseline in Percentage On-time Without or With Non-troublesome Dyskinesia at Week 18
Percentage of on-timePramipexole ERPramipexole IR
Change From Baseline in Percentage On-time Without or With Non-troublesome Dyskinesia at Week 186.855 ± 1.56727.476 ± 1.5973
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.7843 · Mean difference (final values): 0.621 · 95% CI -3.848 to 5.090
SecondaryChange From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18

Percentage on-time with troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as troublesome if it interfered with function or caused meaningful discomfort. Decrease in the percentage represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · Percentage of on-time
Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18
Percentage of on-timePramipexole ERPramipexole IR
Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18-0.142 ± 0.33980.226 ± 0.3463
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.4529 · Median difference (final values): 0.369 · 95% CI -0.598 to 1.335
SecondaryChange From Baseline in Duration of On-time Without Dyskinesia at Week 18

Duration of on-time without Dyskinesia based on patient diary data. On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Increase in the duration represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · hours
Change From Baseline in Duration of On-time Without Dyskinesia at Week 18
hoursPramipexole ERPramipexole IR
Change From Baseline in Duration of On-time Without Dyskinesia at Week 181.026 ± 0.30760.496 ± 0.3134
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.2338 · Mean difference (final values): -0.530 · 95% CI -1.405 to 0.345
SecondaryChange From Baseline in Duration of On-time With Non-troublesome Dyskinesia at Week 18

Duration on-time with non-troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as non-troublesome if it did not interfere with function or did not cause meaningful discomfort. Increase in the duration represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · hours
Change From Baseline in Duration of On-time With Non-troublesome Dyskinesia at Week 18
hoursPramipexole ERPramipexole IR
Change From Baseline in Duration of On-time With Non-troublesome Dyskinesia at Week 18-0.044 ± 0.17400.518 ± 0.1773
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.0263 · Mean difference (final values): 0.562 · 95% CI 0.067 to 1.057
SecondaryChange From Baseline in Duration of On-time Without or With Non-troublesome Dyskinesia at Week 18

Duration of on-time without Dyskinesia or with non-troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as non-troublesome if it did not interfere with function or did not cause meaningful discomfort. Increase in the duration represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · hours
Change From Baseline in Duration of On-time Without or With Non-troublesome Dyskinesia at Week 18
hoursPramipexole ERPramipexole IR
Change From Baseline in Duration of On-time Without or With Non-troublesome Dyskinesia at Week 180.982 ± 0.25831.013 ± 0.2632
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.9337 · Mean difference (final values): 0.031 · 95% CI -0.704 to 0.766
SecondaryChange From Baseline in Duration of On-time With Troublesome Dyskinesia at Week 18

Duration of on-time with troublesome Dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period during which a patient was relatively free of Parkinsons symptoms (e.g. mobile or capable of moving with relative ease and independence). Dyskinesia qualified as troublesome if it interfered with function or caused meaningful discomfort. Decrease in the duration represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · hours
Change From Baseline in Duration of On-time With Troublesome Dyskinesia at Week 18
hoursPramipexole ERPramipexole IR
Change From Baseline in Duration of On-time With Troublesome Dyskinesia at Week 18-0.000 ± 0.05530.031 ± 0.0564
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.6995 · Mean difference (final values): 0.031 · 95% CI -0.127 to 0.188
SecondaryClinical Global Impression of Improvement (CGI-I) Responder at Week 18

CGI-I was used to assess the overall status of Parkinsons disease (PD) after interviewing the patient about the various aspects of the PD and after evaluating adverse events and concomitant treatments. Ranging from 1 point=very much improved to 7 points=very much worse. Responders were defined as patients having score 1 or 2 (at least much improved) when comparing the past week to the assessment at baseline.

Time frame:
18 weeks
Reported as:
Number · Participants
Clinical Global Impression of Improvement (CGI-I) Responder at Week 18
ParticipantsPramipexole ERPramipexole IR
Responder125138
Non-Responder9995
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · Cochran-Mantel-Haenszel · p = 0.3170
SecondaryPatient Global Impressions of Improvement (PGI-I) Responder at Week 18

The PGI-I scale is a patient-rated instrument which was used to measure the improvement of a patients PD symptoms throughout the study. Ranging from 1 point=very much better to 7 points=very much worse. Responders were defined as patients having score 1 or 2 (at least much better) when comparing the past week to the assessment at baseline.

Time frame:
18 weeks
Reported as:
Number · Participants
Patient Global Impressions of Improvement (PGI-I) Responder at Week 18
ParticipantsPramipexole ERPramipexole IR
Responder119127
Non-Responder109109
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · Cochran-Mantel-Haenszel · p = 0.4756
SecondaryResponder in UPDRS Parts II+III Score at Week 18

Responders were defined as patients with at least a 20 percent improvement of UPDRS II+III score relative to baseline. UPDRS II+III ranges 0-160 scores from best to worst and was calculated as the sum of Part II (activities of daily living, ranges from 0 to 52) and Part III (motor examination, ranges from 0 to 108).

Time frame:
Baseline and week 18
Reported as:
Number · Participants
Responder in UPDRS Parts II+III Score at Week 18
ParticipantsPramipexole ERPramipexole IR
Responder164154
Non-Responder6482
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · Cochran-Mantel-Haenszel · p = 0.1051
SecondaryChange From Baseline in UPDRS II Score Separately at Week 18

UPDRS Part II (activities of daily living) ranges from 0 to 52. Reduction over time represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · Units on a scale
Change From Baseline in UPDRS II Score Separately at Week 18
Units on a scalePramipexole ERPramipexole IR
Change From Baseline in UPDRS II Score Separately at Week 18-3.750 ± 0.2235-3.596 ± 0.2197
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.6237 · Mean difference (final values): 0.154 · 95% CI -0.463 to 0.771
Other pre-specifiedChange From Baseline in Epworth Sleepiness Scale (ESS) Total Score at 18 Weeks

ESS is a patient-report scale with 8 items rating how likely one is to fall asleep during passive and inconsequential situations such as watching television, more active situations such as sitting and talking to someone, or consequential situations such as sitting in a car, while stopped for a few minutes in traffic. The likelihood of dozing off is rated from 0 points (no chance) to 3 points (high chance). The overall rating scale is scored from 0 (no daytime sleep) to 24 (worst daytime sleep).

Time frame:
Baseline and week 18
Reported as:
Mean · Units on a scale
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at 18 Weeks
Units on a scalePramipexole ERPramipexole IR
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at 18 Weeks0.1 ± 3.43-0.0 ± 3.38
SecondaryChange From Baseline in UPDRS III Score Separately at Week 18

UPDRS Part III (motor examination) ranges from 0 to 108. Reduction over time represents an improvement. Means are adjusted for treatment, centre and baseline.

Time frame:
Baseline and week 18
Reported as:
Least squares mean · Units on a scale
Change From Baseline in UPDRS III Score Separately at Week 18
Units on a scalePramipexole ERPramipexole IR
Change From Baseline in UPDRS III Score Separately at Week 18-10.068 ± 0.5048-9.440 ± 0.4962
Statistical analysis
  • Pramipexole ER vs Pramipexole IR · ANCOVA · p = 0.3760 · Mean difference (final values): 0.628 · 95% CI -0.765 to 2.021
SecondaryLevodopa (L-Dopa) Introduction During the Study

Number of patients without concomitant L-Dopa treatment at baseline which required L-Dopa supplementation during the study.

Time frame:
18 weeks
Reported as:
Number · Participants
Levodopa (L-Dopa) Introduction During the Study
ParticipantsPramipexole ERPramipexole IR
with L-Dopa introduction10
without L-Dopa introduction2440
SecondaryLevodopa (L-Dopa) Dose Change During the Study

Although the number of patients who began the study with concomitant L-dopa supplementation and required a change in dosage was not analysed for this study, the change from baseline in L-dopa dose is presented.

Time frame:
18 weeks
Reported as:
Mean · mg
Levodopa (L-Dopa) Dose Change During the Study
mgPramipexole ERPramipexole IR
Levodopa (L-Dopa) Dose Change During the Study-5.17 ± 51.563-11.22 ± 101.913

Adverse events

Collected over Up to 18 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pramipexole ER—6/234 (2.6%)93/234 (39.7%)
Pramipexole IR—13/239 (5.4%)90/239 (37.7%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPramipexole ERPramipexole IR
Femur fractureInjury, poisoning and procedural complications0/2342/239
Humerus fractureInjury, poisoning and procedural complications0/2342/239
Acute coronary syndromeCardiac disorders1/2341/239
Cardiac failure chronicCardiac disorders1/2340/239
Cor pulmonaleCardiac disorders1/2340/239
FractureInjury, poisoning and procedural complications1/2340/239
Cerebral infarctionNervous system disorders1/2340/239
Transient ischaemic attackNervous system disorders1/2340/239
Uterine polypReproductive system and breast disorders1/2340/239
Angina pectorisCardiac disorders0/2341/239
Most frequent other events
Most frequent other events
EventPramipexole ERPramipexole IR
SomnolenceNervous system disorders51/23435/239
DizzinessNervous system disorders30/23431/239
NauseaGastrointestinal disorders20/23417/239
ConstipationGastrointestinal disorders17/23420/239
DyskinesiaNervous system disorders12/23418/239

Baseline characteristics

Treated Set, all randomized patients that received treatment

Age, Continuous
Age, Continuous(years)Pramipexole ERPramipexole IRTotal
Mean62.2 ± 9.1061.8 ± 9.0362.0 ± 9.06
Sex: Female, Male
Sex: Female, Male(Participants)Pramipexole ERPramipexole IRTotal
Female8095175
Male154144298
08

Study locations

20 sites
  • 248.671.86004 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 248.671.86006 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 248.671.86007 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 248.671.86020 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 248.671.86012 Boehringer Ingelheim Investigational Site
    Chengdu, China
  • 248.671.86013 Boehringer Ingelheim Investigational Site
    Chongqing, China
  • 248.671.86014 Boehringer Ingelheim Investigational Site
    Chongqing, China
  • 248.671.86008 Boehringer Ingelheim Investigational Site
    Guangzhou, China
  • 248.671.86009 Boehringer Ingelheim Investigational Site
    Guangzhou, China
  • 248.671.86017 Boehringer Ingelheim Investigational Site
    Hangzhou, China
  • 248.671.86018 Boehringer Ingelheim Investigational Site
    Hangzhou, China
  • 248.671.86005 Boehringer Ingelheim Investigational Site
    Jinan, China
  • 248.671.86002 Boehringer Ingelheim Investigational Site
    Nanjing, China
  • 248.671.86001 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 248.671.86003 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 248.671.86010 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 248.671.86011 Boehringer Ingelheim Investigational Site
    Shenyang, China
  • 248.671.86019 Boehringer Ingelheim Investigational Site
    Suzhou, China
  • 248.671.86015 Boehringer Ingelheim Investigational Site
    Wuhan, China
  • 248.671.86016 Boehringer Ingelheim Investigational Site
    Wuhan, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Aug 31, 2010
Start
Aug 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Jan 24, 2013
Last update
Oct 31, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01191944
Responsible party
Sponsor
First posted
Aug 31, 2010
Start date
Aug 2010
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Jan 24, 2013
Last update
Oct 31, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion